Weight Loss Solutions

FDA announcement -- significant impact on Tirzepatide

 

On December 19, 2024, the FDA announced that compounding pharmacies must stop producing tirzepatide.  ​

Shortage resolution

• The FDA initially removed tirzepatide from the drug shortage list in October 2024, but after a lawsuit, the agency reevaluated its decision and allowed compounders to continue for a time.

Grace period

• The FDA gave compounders a grace period of 60 to 90 days before enforcing rules that would put a halt to their work.

Exceptions

• Medical aesthetic and weight loss practices may still be able to acquire compounded tirzepatide from compounding pharmacies under certain limited circumstances. 

Transition

• Practices should begin making plans to transition to the name brand.

​

How does this impact you?

Unless you are currently using the brand name Mounjaro or Zepbound, you are receiving the medication tirzepatide through a compounding pharmacy. Compounding pharmacies have been able to offer a greatly reduced price and have had a more reliable supply available to you.

​

Nurtured By Nurses has secured a supply of Tirzepatide that is available as part of our membership program for the next 6 - 12 months. We are limiting the number of participants in our program over the next 60 days to ensure active members can continue receiving the medication at the current price.